The efficacy of Isotretinoin-loaded solid lipid nanoparticles in comparison to Isotrex® on acne treatment
(ندگان)پدیدآور
Layegh, PouranMosallaei, NavidBagheri, DanialJaafari, Mahmoud RezaGolmohammadzadeh, Shivaنوع مدرک
TextResearch Paper
زبان مدرک
Englishچکیده
Topical retinoids are considered as the first line therapy in the treatment of acne vulgaris, but they are associated with cutaneous irritation. In this study, isotretinoin-loaded solid lipid nanoparticles(IT-SLN) were prepared to treat the mild to moderate acne. Also using IT-SLN would minimize IT adverse effects in comparison to commercial product, Isotrex®. This study was conducted to prepare and characterize IT-SLN and assessing the efficiency of IT-SLN comparing to Isotrex® acne. IT-SLN was prepared using hot high pressure homogenization method. IT-SLN contained 0.05% IT in 5% of lipid phase (Glyceryl monostearate- GMS) and tween 80 (2.5 % w/v) was used as surfactant in the aqueous phase. IT-SLN was characterized by particle size analyzing, differential scanning calorimetry and transmission electron microscopy. Encapsulation efficacy was also obtained using spectrophotometry. The efficacy of IT-SLN was evaluated in a randomized, single-blind, parallel-group study and compared with Isotrex®. Forty patients encountered in the study and divided in two groups. Treatment regimen was once-nightly topical administration accompanied with topical administration of clindamycin 2% solution twice a day for 8 weeks. The particle size of IT-SLN was around 60 nm with PDI of 0.4 and zeta potential was about -40 mV. Encapsulation efficacy of IT in SLN in crystalline form was 84±0.21%. IT-SLN produced significantly better treatment than Isotrex® in both non-inflammatory and inflammatory lesions according to its recovery percent after 8 weeks. Also IT-SLN gained better global assessment scores. Our results showed that IT-SLN had higher efficacy than Isotrex® to clear non-inflammatory and inflammatory lesions.
کلید واژگان
Solid lipid nanoparticles (SLN)Isotretinoin
Acne
Clinical trial
شماره نشریه
1تاریخ نشر
2013-10-011392-07-09
ناشر
Mashhad University of Medical Sciencesسازمان پدید آورنده
Research Center for Cutaneous Leishmaniasis, Department of Dermatology, Mashhad University of Medical Sciences, Mashhad, IranSchool of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
شاپا
2322-30492322-5904




